Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: The Di.N.A.S. randomized trial

Journal of the American Society of Nephrology

Volumn 13, Issue 6, 2002, Pages 1615-1625

  Gambaro, Giovanni ^a   Kinalska, Ida ^a   Oksa, Adrian ^a   Pont'uch, Peter ^a   Hertlová, Miluse ^a   Olsovsky, Jindrich ^a   Manitius, Jacek ^a   Fedele, Domenico ^a   Czekalski, Stanislaw ^a   Perusicová, Jindriska ^a   Skrha, Jan ^a   Taton, Jan ^a   Grzeszczak, Wladyslaw ^a   Crepaldi, Gaetano ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; SULODEXIDE; GLYCOSAMINOGLYCAN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; METABOLIC REGULATION; MICROALBUMINURIA; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; ALBUMINURIA; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; GLYCOSAMINOGLYCANS; HUMANS;

EID: 0036014944     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000014254.87188.E5     Document Type: Article

References (45)

1. Incidence and prevalence of ESRD
2. Nephropathy in patients with type 2 diabetes mellitus
3. Twenty-five years of experience with out-center hemodialysis
4. The effect of age, diabetes, and other comorbidity on the survival of patients on dialysis: A systematic quantitative overview of the literature
5. Growth factors and the kidney in diabetes mellitus
6. Microalbuminuria as a predictor of clinical diabetic nephropathy
7. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies
8. Microalbuminuria, endothelial dysfunction and cardiovascular risk
9. Albuminuria reflects widespread vascular damage. The Steno hypothesis
10. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
11. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
12. Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice
13. Glycosaminoglycan therapy for long-term diabetic complications?
14. Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats
15. Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy
16. Increased glomerular α1(IV) collagen expression and deposition in long-term diabetic rats is prevented by chronic glycosaminoglycan treatment
17. Glycosaminoglycan therapy prevents TGF-β overexpression and pathologic changes in renal tissue of long-term diabetic rats
18. The observation of heparin on endothelium after injection
19. Effect of low-dose heparin on urinary albumin excretion in insulin-dependent diabetes mellitus
20. Effect of sulfated glycosaminoglycans on albuminuria in patients with overt diabetic (type-1) nephropathy
21. Danaparoid sodium lowers proteinuria in diabetic nephropathy
22. Therapy with glycosaminoglycans lowers albumin excretion rate in non-insulin dependent diabetic patients with microalbuminuria
23. Glycosaminoglycan sulodexide decreases albuminuria in diabetic patients
24. Effect of glycosaminoglycans on urinary albumin excretion in insulin-dependent diabetic patients with micro- or macroalbuminuria
25. A randomized, controlled study of sulodexide therapy for the treatment of diabetic nephropathy
26. A pilot study of the effect of the glycosaminoglycan sulodexide on microalbuminuria in type 1 diabetic patients
27. Glycosaminoglycans oral therapy reduces microalbuminuria, blood fibrinogen levels and limb arteriopathy clinical signs in patients with non-insulin dependent diabetes mellitus
28. Glycosaminoglycans delay the progression of nephropathy in NIDDM
29. The influence of glycosaminoglycan sulodexide on albuminuria in type I diabetics
30. The need for early predictors of diabetic nephropathy risk. Is albumin excretion rate sufficient?
31. Glomerular permselectivity factors are not responsible for the increase in fractional clearance of albumin in rat glomerulonephritis
32. Glomerular processing of dextran sulfate during transcapillary transport
33. Albuminuria in patients with type 1 diabetes is directly linked to changes in the lysosome-mediated degradation of albumin during renal passage
34. Mechanisms of proteinuria in diabetic nephropathy: A study of glomerular barrier function
35. Glycosaminoglycans: Use in treatment of diabetic nephropathy
36. Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy
37. Heparin stimulates the synthesis and modifies the sulfation pattern of heparan sulfate proteoglycan from endothelial cells
38. Enalapril improves albuminuria by preventing glomerular loss of heparan sulfate in diabetic rats
39. Protein overload stimulates RANTES production by proximal tubular cells depending on NF-κB activation
40. Possible role of glycated albumin filtered during diabetic glomerulopathy, in the activation of tubular cells and progression of the diabetic nephropathy
41. Tubular catabolism of albumin is associated with the release of an inflammatory lipid
42. Transcapillary escape rate and albuminuria in type II diabetes. Effects of short term treatment with low-molecular weight heparin
43. IPO-V2: A prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction
44. Effect of danaparoid sodium on proteinuria, von Willebrand factor, and hard exudates in patients with diabetes mellitus
45. Effect of danaparoid sodium on hard exudates in diabetic retinopathy